[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350368-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350368-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","utilization-of-invasive-mediastinal-nodal-staging-and-prevalence-of-occult-nodal-disease-in-patients-with-synchronous-primary-lung-cancers","Utilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers","","Guidelines recommend invasive mediastinal nodal staging (IMNS) for patients with synchronous primary lung cancer (SPLC) who are candidates for curative resection. Prevalence of occult mediastinal nodal disease and selective IMNS use were evaluated in patients suspected on preoperative imaging who underwent resection from 2000 to 2022. Univariable analysis identified clinicopathologic risk factors. Proposed low-risk criteria required peripheral, subsolid tumors ≤3 cm, SUVmax \u003C3.6, and PET-negative lymph nodes. Among 484 eligible patients, only 19% received IMNS; occult nodal disease was found in 14% after exclusions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/utilization-of-invasive-mediastinal-nodal-staging-and-prevalence-of-occult-nodal-disease-in-patients-with-synchronous-primary-lung-cancers/350368/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/utilization-of-invasive-mediastinal-nodal-staging-and-prevalence-of-occult-nodal-disease-in-patients-with-synchronous-primary-lung-cancers/350368.png","ImageObject",300,407,{"name":42,"@type":43},"Stanley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was invasive mediastinal nodal staging (IMNS) investigated in patients with synchronous primary lung cancers?","Question",{"text":63,"@type":64},"Guidelines recommend IMNS for curable resection candidates with synchronous primary lung cancer, but the true prevalence of occult nodal disease and how selectively IMNS should be used were not well defined.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What low-risk criteria were proposed to identify patients less likely to have occult nodal disease?",{"text":68,"@type":64},"Criteria included all primary tumors being peripheral and subsolid, each ≤3 cm on preoperative CT, SUVmax \u003C 3.6, and lymph nodes being PET negative.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key prevalence findings after applying exclusions related to clinical nodal disease?",{"text":72,"@type":64},"After excluding patients with clinical nodal disease on IMNS and/or imaging, 472 patients remained; occult nodal disease occurred in 14% (68/472), including occult N2 disease in 5.9% (28/472).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350368,1790587831,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Lung Cancer. Author manuscript; available in PMC 2026 June 03. |\n| --- | --- |\n\nPublished in final edited form as:  \nLung Cancer. 2026 June ; 216: 109420. doi:10.1016/j.lungcan.2026.109420 .  \nUtilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers  \nNanruoyi Zhoua, Stella Tsuia, Nicolas Toumbacarisb, Kay See Tanb, Joseph Dycocoa, Alexis P. Chidia, Katherine D. Graya, Smita Sihaga, Bernard J. Parka, Matthew J. Botta, Prasad S. Adusumillia, Daniela Molenaa, Valerie W. Ruscha, James Huanga, Manjit S. Bainsa, Gaetano Roccoa, James M. Isbella, David R. Jonesa,*  \naThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States  \nb Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States  \nAbstract  \nBackground: Guidelines recommend invasive mediastinal nodal staging (IMNS) for patients with synchronous primary lung cancer (SPLC) who are candidates for curative resection. We investigated the prevalence of occult nodal disease and selective use ofIMNS in patients with SPLC.  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*Corresponding author at: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 7, New York, NY 10065, [United States. Jonesd2@mskcc.org](United States. Jonesd2@mskcc.org) (D.R. Jones).  \nCRediT authorship contribution statement  \nNanruoyi Zhou: Writing – original draft, Visualization, Methodology, Investigation, Data curation, Conceptualization. Stella Tsui: Writing – review & editing, Investigation, Data curation. Nicolas Toumbacaris: Writing – review & editing, Formal analysis. Kay See Tan: Writing – review & editing, Formal analysis. Joseph Dycoco: Data curation. Alexis P. Chidi: Writing – review & editing, Methodology. Katherine D. Gray: Writing – review & editing. Smita Sihag: Writing – review & editing. Bernard J. Park: Writing – review & editing, Methodology. Matthew J. Bott: Writing – review & editing. Prasad S. Adusumilli: Writing – review & editing, Methodology, Conceptualization. Daniela Molena: Writing – review & editing. Valerie W. Rusch: Writing – review & editing. James Huang: Writing – review & editing. Manjit S. Bains: Writing – review & editing. Gaetano Rocco: Writing – review & editing. James M. Isbell: Writing – review & editing. David R. Jones: Writing – review & editing, Supervision, Resources, Methodology, Funding acquisition, Conceptualization.  \nDeclaration of competing interest  \nPrasad S. Adusumilli declares research funding from ATARA Biotherapeutics, is a scientific advisory board member and consultant for ATARA Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, Johnson & Johnson, Orion, and Outpace Bio, has patents, royalties, and intellectual property on mesothelin-targeted chimeric antigen receptor and other T-cell therapies, which have been licensed to ATARA Biotherapeutics, and has an issued patent method for detection of cancer cells using virus and pending patent applications on PD-1 dominant negative receptor, a wireless pulse-oximetry device, and an ex vivo malignant pleural effusion culture system. Gaetano Rocco has a financial relationship with Scanlan, Merck, and Medtronic. Valerie W. Rusch reports grant support from Genelux and Genentech and travel support from Intuitive Surgical and National Institutes of Health/Coordinating Center for Clinical Trials. Daniela Molena serves on a steering committee for AstraZeneca, consults for Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, and Boston Scientific, and has been an invited speaker fo","cbCaiaqt5uiTIPwO","https://ap.wps.com/l/cbCaiaqt5uiTIPwO","pdf",663179,"English","# Abstract\n## Background\n## Methods\n## Proposed low-risk criteria\n## Results\n## Competing interest and author contributions","[{\"question\":\"Why was invasive mediastinal nodal staging (IMNS) investigated in patients with synchronous primary lung cancers?\",\"answer\":\"Guidelines recommend IMNS for curable resection candidates with synchronous primary lung cancer, but the true prevalence of occult nodal disease and how selectively IMNS should be used were not well defined.\"},{\"question\":\"What low-risk criteria were proposed to identify patients less likely to have occult nodal disease?\",\"answer\":\"Criteria included all primary tumors being peripheral and subsolid, each ≤3 cm on preoperative CT, SUVmax \\u003c 3.6, and lymph nodes being PET negative.\"},{\"question\":\"What were the key prevalence findings after applying exclusions related to clinical nodal disease?\",\"answer\":\"After excluding patients with clinical nodal disease on IMNS and/or imaging, 472 patients remained; occult nodal disease occurred in 14% (68/472), including occult N2 disease in 5.9% (28/472).\"}]","Utilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers | PDF",1790088707,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b98bdd5a8a68eaeb58a2b6ed7be98bf2.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e84f36625986ce510256a80811b9a99.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae770b67cb6e4a8afa08ca20260b424a.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b00f86b4912e425015321710a424eda1.webp",980,1268]